EWG Elevate’s Nektar Therapeutics NKTR Stock Holding History

EWG Elevate’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,506	Closed	-$403K	–	70
2020 Q1	$403K	Buy	1,506 +331	+28%	+$102K	0.3%	43
2019 Q4	$380K	Buy	+1,175	New	+$341K	0.21%	60

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

EWG Elevate's NKTR Position: Q2 2020 in Review

EWG Elevate sold out of Nektar Therapeutics (NKTR) in Q2 2020, closing a stake of 1,506 shares — an estimated $403K sold.

EWG Elevate first reported a position in NKTR in Q4 2019 and held it in 2 quarters. The position peaked at $403K in Q1 2020. 260 funds tracked by Wall St. Rank hold NKTR as of Q2 2020.

EWG Elevate reported no remaining Nektar Therapeutics position as of Q2 2020 after selling out during the quarter.
EWG Elevate sold 1,506 Nektar Therapeutics shares in Q2 2020, an estimated $403K.
EWG Elevate first reported a position in Nektar Therapeutics in Q4 2019 and held it in 2 quarters.
EWG Elevate's Nektar Therapeutics position peaked at $403K in Q1 2020.
260 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2020.

Based on EWG Elevate's 13F filing for Q2 2020, filed 7 Jul 2020.